Virtual Poster Session on Targeted Therapies in Sarcoma - priME Oncology
Virtual Poster
Virtual Poster

Virtual Poster Session on Targeted Therapies in Sarcoma

Select Data Presented During the 2019 Oncology Annual Meeting in Chicago

Not a member of My prIME? Join now for instant access.

This activity features presentations and downloadable slides highlighting the use of targeted therapies in soft tissue sarcoma and gastrointestinal stromal tumors

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides



0.5 AMA PRA Category 1 Credit(s)

Release Date

Release Date

Jun 14, 2019

Expiration Date

Jun 14, 2020

Olivier Mir, MD, PhD, MPH

Abstract #11021: A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib (REG) in patients (pts) with nonadipocytic soft tissue sarcoma (STS) previously treated with pazopanib (PAZ)

Featured Expert: Olivier Mir, MD, PhD, MPH

Michael Heinrich, MD

Abstract #11022: Clinical activity of avapritinib in ≥ fourth-line (4L+) and PDGFRA exon 18 gastrointestinal stromal tumors

Featured Expert: Michael Heinrich, MD

  • Michael Heinrich, MDOregon Health and Science University
    Portland, Oregon, United States
  • Olivier Mir, MD, PhD, MPHInstitut Gustave Roussy
    University of Paris-Sud
    Villejuif, France

This activity is designed for clinicians who are sarcoma specialists.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the key data about targeted therapy for sarcomas from the conference
  • Have greater competence related to applying key data from the conference to clinical practice, as appropriate for patients with soft tissue sarcoma or gastrointestinal stromal tumors

This educational activity is supported by grants from Bayer HealthCare Pharmaceuticals, Inc.; Jazz Pharmaceuticals; and Merck and Co, Inc.

Continuing Education

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database and in your My prIME account. You can download your certificate as needed. Technical requirements may be found under the Terms of Use.

Estimated time to complete activity: 0.5 hour(s)

To contact Postgraduate Institute for Medicine please visit

Disclosure of Relevant Financial Relationships

Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Heinrich has disclosed that he has received royalty fees (paid to his institution) from Novartis. He has also received consulting fees from Blueprint, Deciphera, and Molecular MD. He has performed contracted research for Deciphera. He has less than 5% ownership interest in Molecular MD. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Mir has disclosed that he has received consulting fees Eli Lilly, Janssen, Pfizer, Roche, and Servier. He has also received fees for non-CME/CE services from Roche and Servier. He also disclosed ownership interest (less than 5%) in Amplitude Surgical and Transgene. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Postgraduate Institute for Medicine Planners and Managers have disclosed no relevant financial relationships.

The employees of prIME Oncology have disclosed:

  • Elaine Hamarstrom, PhD (scientific content manager) – no relevant financial relationships
  • Trudy Stoddert, ELS (editorial content reviewer) – worked on non–CME certified projects in the last 12 months supported by Array; AstraZeneca; F. Hoffmann-La Roche Ltd; Ipsen; Merck KGaA, Darmstadt, Germany; Pfizer; Servier; and Shire

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.